Clinical reviewer: Dr. Sarah Boss, MD

This guide is published by COGNIFUL, part of THE BALANCE GROUP. It compares selected UK care routes and our potential residential role abroad. Inclusion does not imply an independent ranking or that every provider offers the same medication service, admission criteria or accommodation.

Ask the professional responsible for the prescription to review the current situation, or seek an appropriate assessment if that relationship is no longer available. The history should include actual use, earlier changes, withdrawal-related experiences, other medicines and the original reason for treatment. A new provider should understand what has already been tried before recommending a program.

The NHS describes GP and local drug treatment services as routes to help. For benzodiazepines, verify which local service handles prescribed dependence and how specialist review is arranged. A general drug-service pathway should not be assumed to offer the same prescribing support in every area or for every medication concern. [3]

The joint guideline distinguishes physical dependence from substance use disorder. A person who followed a prescription may still become dependent without addiction. Ask the assessor to explain the diagnosis and the purpose of care: medical review, treatment of harmful use, support for the original condition or a combination. [1]

Priory Hospital Roehampton publishes medically assisted detox and inpatient addiction treatment, as well as day and outpatient care. Ask about the specific benzodiazepine pathway, medical exclusions and how the team coordinates a plan that continues after discharge. Its published prescription-drug services are a reason to inquire, not a guarantee that a standard package fits every history. [4] [6]

Local care may provide useful continuity with the prescriber who knows the person. A private admission should explain how it will communicate with that clinician and whether follow-up has been accepted. Private funding and an available bed do not themselves settle responsibility for the period after discharge.

COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. A person should not book travel on the assumption that medication management transfers automatically with them. Medical suitability, prescribing responsibility and the next appointment must be made explicit before any proposed admission. [2]

The joint guideline recognizes outpatient management for many people, while some situations call for inpatient care because of significant risks, unstable health or severe withdrawal concerns. Ask which factors support the proposed level of care. A medical recommendation should follow the history and current condition rather than the budget or preferred length of leave. [1]

Tell the team about past seizures, severe withdrawal, overdose and major psychiatric events. Include alcohol, other prescribed medicines and nonprescribed substances. When information is uncertain, state the uncertainty. The provider should explain what records or assessment are needed before it can confirm the appropriate setting.

If outpatient care is recommended, ask who provides clinical review and how concerns are escalated. Outpatient treatment does not mean being left to manage withdrawal independently. If inpatient treatment is recommended, ask what the admission aims to address and which criteria guide discharge and follow-up. [1]

The FDA warns that abruptly stopping or rapidly reducing benzodiazepines can cause severe withdrawal, including seizures. This warning applies even when dependence followed prescribed use. Do not change medication independently before an assessment, admission or flight. The responsible clinician should determine the approach and appropriate oversight. [7]

The guideline recognizes that an individualized process can take a prolonged period for some people. Ask how the provider handles a plan that extends beyond a short admission and which UK professional accepts continuing review. A statement that a program lasts a certain number of weeks does not establish that every medical need will be resolved within it. [1]

Clarify what happens if symptoms change or the initial recommendation needs revision. The person should know whom to contact and which issues require medical reassessment. They should not be expected to diagnose every symptom or feel pressure to meet a travel deadline at the expense of clinical review.

The joint guideline supports concurrent treatment of co-occurring conditions. If the medication was prescribed for anxiety, insomnia or another concern, ask what professional support is available for that condition. The medical process should not leave the original problem outside the plan or assume that it will resolve automatically. [1]

For chronic insomnia, the National Heart, Lung, and Blood Institute identifies cognitive behavioral therapy for insomnia as a usual first option. Ask about appropriate sleep assessment and access to relevant treatment. This does not establish a dedicated insomnia service or a particular therapy at every detox provider or at COGNIFUL. [8]

Withdrawal-related symptoms, recurrence of the original condition and other health problems may need to be distinguished over time. The guideline recognizes the complexity of that assessment. Ask how the team listens to physical and psychological concerns and what support remains available when the course is less straightforward than expected. [1]

The FDA warns of serious risks involving benzodiazepines together with opioids, alcohol and other substances. Give the clinician the complete account, including occasional use and prescriptions from several sources. A medically useful plan needs a coordinated view of these factors rather than separate instructions for each drug. [7]

If opioid use disorder is also present, the CDC recommends medication treatment and advises against detoxification alone. Ask how that treatment is preserved through any benzodiazepine-related admission or overseas stay. The individual should not discover at a transfer that one service expected another to organize essential care. [9]

An overseas residential stay should have a specific therapeutic purpose once the medical plan is appropriate. Ask what the proposed setting adds to work that could occur locally and how it connects to existing care. A change of environment may be a preference, but it does not remove the need for a responsible prescriber and accepted follow-up.

Discuss medication and travel requirements with the appropriate clinicians and authorities before making arrangements. A UK prescription should not be assumed to transfer unchanged to Spain. The receiving provider needs the relevant records and must confirm that the current medical requirements fit the proposed setting.

Plan the return appointment before departure. Agree what the UK professional will receive and which responsibilities they have accepted. With the client’s consent, family members may help coordinate appointments and records, but should not become the sole communication channel between clinicians. The person should also have a clear explanation of the next steps.

COGNIFUL’s published prescription-medication service and clinical standards require consideration of withdrawal risk, current medical and psychiatric needs and fit with the shared Mallorca residence. COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. A medical or acute-care service may be needed first, and the clinical sequence should be settled before residential plans are finalized. [10] [2]

For a suitable person, the proposed residential work should address actual goals, such as coping, relationships, patterns around harmful use and reintegration. Prescribed dependence without addiction should be described accurately. Ask which professionals provide the proposed work and how it connects with the existing medical plan.

Admission should not be based on a universal assumption that every medication change must already be complete. The relevant question is whether the current needs, prescribing and external medical arrangements can be appropriately supported and have been accepted. A suitability review should explain those conditions for the individual. [2]

The residence takes a maximum of four clients at a time, each with a private suite. Clinical and bodywork sessions are individual. The residence, chef, personal manager, other holistic sessions, activities and excursions are shared. This defines the setting and session format, without establishing continuous physician presence, a staffing ratio or hospital equipment. [5]

COGNIFUL Premier and Premier Plus both include assessment, a personal plan and continuing-care planning. Plus adds individual therapeutic work, family and transition work, and three months of aftercare. Base-program follow-up is individually agreed. The typical four-to-twelve-week stay is reviewed for each client and is not a benzodiazepine withdrawal deadline. [5] View program fees

Request a written proposal covering duration, total costs, inclusions and separately arranged medical services. The program generally operates through self-payment, without direct insurer billing or guaranteed reimbursement. Ask how the agreed follow-up connects to the UK clinician and which appointments are accepted. Do not assume unrestricted remote prescribing from an overseas residence. [5] [11]

• What diagnosis and history support the proposed treatment?
• Which UK clinician coordinates withdrawal-related medical decisions?
• How are the original symptoms and other medications managed?
• What care continues if the process extends beyond the admission?
• Has the UK follow-up professional accepted the return plan?

A well-defined pathway may remain in the UK or include a suitable residential stage abroad. Each part should have a clear purpose and responsible professional. The proposed accommodation and travel should remain adaptable to the medical recommendation.

Does dependence mean I have an addiction?

Not necessarily. Physical dependence can occur during prescribed benzodiazepine use without a substance use disorder. Assessment should explain the distinction and appropriate care. [1]

Must benzodiazepine withdrawal be inpatient?

No. Many people can receive outpatient care; some need inpatient treatment because of assessed risks. A clinician should determine the suitable setting. [1]

Can I stop medication to prepare for admission?

Do not independently alter medication for an admission. Abrupt stopping or rapid reduction can cause serious withdrawal and requires appropriate medical guidance. [7]

Is COGNIFUL a UK benzodiazepine-detox provider?

COGNIFUL in Mallorca, Spain, offers detoxification as part of its addiction treatment pathway. A possible residential stay requires individual suitability review. [5] [2]

COGNIFUL admissions can explain what information is needed from the UK treating team. Share the current plan and remaining medical requirements. A seizure, suspected overdose, breathing difficulty, severe confusion or immediate danger requires urgent local help before an international journey. [5] [7]

1. Joint Clinical Practice Guideline on Benzodiazepine Tapering — American Society of Addiction Medicine and partner societies.
2. Clinical scope, suitability and care coordination — COGNIFUL.
3. Drug addiction: getting help — NHS.
4. Priory Hospital Roehampton — Priory.
5. COGNIFUL programs, fees, admissions and suitability — COGNIFUL.
6. Prescription drug withdrawal and detox — Priory.
7. Benzodiazepine safety communication — US Food and Drug Administration.
8. Insomnia treatment — National Heart, Lung, and Blood Institute.
9. Opioid use disorder: treating — Centers for Disease Control and Prevention.
10. Prescription medication concerns and residential treatment — COGNIFUL.
11. Reintegration and continuing care — COGNIFUL.

Primary clinical and provider pages accessed October 18, 2026. Individual services, admission and fees should be confirmed directly.